Summary
Prostate cancer is the second most common cancer in men, and accounts for 9 % of all cancer deaths in men. Currently, it is hard to predict which patients will respond best to different treatments, and which patients can be managed safely without undergoing treatment. The aim of PIONEER is to use big data to address key knowledge gaps related to the screening, diagnosis and treatment of prostate cancer patients. To do this, they will standardise and integrate existing ‘big data’ from sources such as clinical trials and electronic health records into a single, innovative data platform. The project will draw on this database to identify ways to improve prostate cancer outcomes and health system efficiency. The project will apply FAIR (‘findable, accessible, interoperable, and reusable’) principles to the data. Ultimately, the project results should feed back into clinical centres so that patients can benefit from the best possible care.
PIONEER is part of IMI’s Big Data for Better Outcomes (BD4BO) programme.
Achievements & News
December 2022
Prostate cancer is the second most common cancer in men and its diagnosis - and treatment - can take a...
April 2025
How can IHI and IMI projects harness the opportunities posed by real-world data and AI to make Europe a leader...
May 2023
Three IMI projects have contributed to UroEvidenceHub, a platform that will provide physicians with personalised healthcare recommendations for patients with...
The first two datasets have been added to the PIONEER big data platform, a major milestone for the IMI project. The researchers want to use real-world data from well-known prostate cancer studies to answer some vital questions about the disease. ###The first question they hope the data will help answer concerns the kind of variables that affect the prognosis for prostate cancer patients.
The two datasets will be followed by more; other partners are poised to add another 22 anonymised datasets to the platform, and PIONEER hopes that other data custodians, both private and public, will be encouraged to contribute. The ultimate aim is to improve the health and social care for all prostate cancer patients and their families.
Analytics will be run over the lifetime of the project to account for new and updated datasets. Both the OMOP/OHDSI platform for population-based registries and epidemiological research and the PIONEER omics analysis platform for cohort and clinical trial data were set up by The Hyve, a partner in the project.
Read more
- IMI’s news story
- Project website
- Project factsheet
- Follow @ProstatePioneer on Twitter
Participants
Show participants on mapUniversities, research organisations, public bodies, non-profit groups
- Association Eisbm, Vourles, France
- Astellas Pharma Europe BV, Leiden, Netherlands
- Astrazeneca AB, Sodertaelje, Sweden
- Bayer Aktiengesellschaft, Leverkusen, Germany
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- European Alliance for Personalised Medicine, Maribor, Slovenia
- European Cancer Patient Coalition, Bruxelles / Brussel, Belgium
- European Organisation For Research And Treatment Of Cancer Aisbl, Bruxelles / Brussel, Belgium
- Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., Munchen, Germany
- Goeteborgs Universitet, Goeteborg, Sweden
- Helmholtz-Zentrum Dresden-Rossendorf Ev, Dresden, Germany
- Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden
- Imperial College Of Science Technology And Medicine, London, United Kingdom
- Ims Information Solutions Medical Research Limited, London, United Kingdom
- International Consortium For Healthoutcomes Measurement LTD, Erith, United Kingdom
- Janssen Pharmaceutica Nv, Beerse, Belgium
- King'S College London, London, United Kingdom
- Labcorp Early Development Laboratories Limited, Harrogate, United Kingdom
- Lunds Universitet, Lund, Sweden
- Nv SAS Institute SA, Tervuren, Belgium
- Orion Oyj, Espoo, Finland
- PNO Life Sciences & Health B.V., Rijswijk, Netherlands
- Pinsent Masons Llp, London, United Kingdom
- Sanofi-Aventis Recherche & Developpement, Gentilly, France
- Stichting European Urological Foundation, Arnhem, Netherlands
- Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
- Tampereen Korkeakoulusaatio Sr, Tampere, Finland
- Technische Universitaet Dresden, Dresden, Germany
- The Ecancer Global Foundation, Bristol, United Kingdom
- The Hyve BV, Utrecht, Netherlands
- The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom
- Universita Vita-Salute San Raffaele, Milano, Italy
- Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
- Weizmann Institute Of Science, Rehovot, Israel
| Participants | |
|---|---|
| Name | EU funding in € |
| Association Eisbm | 758 200 |
| Cancer Intelligence Limited (left the project) | 12 121 |
| Erasmus Universitair Medisch Centrum Rotterdam | 415 349 |
| European Alliance for Personalised Medicine | 180 000 |
| European Cancer Patient Coalition | 69 994 |
| European Organisation For Research And Treatment Of Cancer Aisbl | 16 000 |
| Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | 125 000 |
| Goeteborgs Universitet | 150 650 |
| Helmholtz-Zentrum Dresden-Rossendorf Ev | 101 300 |
| Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag | 175 000 |
| Imperial College Of Science Technology And Medicine | 200 000 |
| International Consortium For Healthoutcomes Measurement LTD | 31 250 |
| King'S College London | 359 000 |
| Lunds Universitet | 185 761 |
| Pinsent Masons Llp | 188 800 |
| PNO Life Sciences & Health B.V. | 237 500 |
| Stichting European Urological Foundation | 797 439 |
| Stichting Radboud Universitair Medisch Centrum | 124 922 |
| Stichting Radboud Universiteit (left the project) | 25 078 |
| Tampereen Korkeakoulusaatio Sr | 212 500 |
| Technische Universitaet Dresden | 125 000 |
| The Ecancer Global Foundation | 37 333 |
| The Hyve BV | 400 000 |
| The University Court Of The University Of Aberdeen | 409 303 |
| Universita Vita-Salute San Raffaele | 312 500 |
| Universitaetsklinikum Hamburg-Eppendorf | 150 000 |
| Weizmann Institute Of Science | 200 000 |
| Total Cost | 6 000 000 |
Alex Asiimwe
Bayer
James N'Dow
Stichting European Urological Foundation